Expert review of gastroenterology & hepatology
-
Obesity constitutes a significant and rapidly increasing public health challenge and is associated with significant co-morbidities and healthcare costs. Although undoubtedly multifactorial, research over the last decade has demonstrated that the microbes that colonize the human gut may contribute to the development of obesity through roles in polysaccharide breakdown, nutrient absorption, inflammatory responses and gut permeability. ⋯ In addition, we and others have shown that the methanogenic Archaea may also contribute to altered metabolism and weight gain in the host. However, much remains to be learned about the roles of different gut microbial populations in weight gain and obesity and the underlying mechanisms before we can begin to approach targeted treatments.
-
Expert Rev Gastroenterol Hepatol · Jan 2015
Multicenter StudyPost-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
To evaluate the safety and efficacy of CT-P13 (Remsima(®)) in patients with inflammatory bowel disease (IBD) in South Korea. ⋯ CT-P13 was well tolerated and efficacious in patients with IBD.